Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501860 · ClinicalTrials.gov registry record · Phase 3
A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution
A Phase 3 study, sponsored by American Genomics.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT05501860 is a Phase 3 study that has completed, run by American Genomics. The registered enrollment target is 249 participants.
The verdict
NCT05501860, a Phase 3 study, has completed, sponsored by American Genomics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..
Interventions
- DRUG Placebo
- DRUG AG-920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2022-07-30 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05501860
The ClinicalTrials.gov registry entry for NCT05501860 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Genomics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05501860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05501860 about?
NCT05501860 is a clinical study titled "A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution". A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..
What is the current status of trial NCT05501860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2022-07-30. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT05501860?
The interventions under investigation include: Placebo (DRUG), AG-920 (DRUG).
Who is sponsoring clinical trial NCT05501860?
This trial is sponsored by American Genomics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.